Clinical trials are an important way to improve treatment for people with cancer. While most are continuing during the COVID-19 pandemic, the period of time that clinical trials are available and recruiting may change quickly. If you would like to get involved in a clinical trial, speak to your treatment team or the health service where the clinical trial is being undertaken, to confirm it is open and appropriate for you. For cancer information and support, call Cancer Council's experienced cancer nurses on 13 11 20 Monday to Friday from 9am-5pm.

MARIPOSA : A Phase 3, Randomized Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib Versus Lazertinib as First-Line Treatment in Patients With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer.

Male or<br/>FemaleGender Male or
Female

RecruitingStatus Recruiting

Systemic<br/>Therapy TrialTypeSystemic
Therapy Trial

ThreePhase Three

18+Age Over 18

Lung<br/>CancersCancer LocationLung
Cancers

Systemic therapy,Treatment | LungNon-Small Cell Lung Cancer

Trial Overview Read MoreRead more

This phase III trial is trying to understand how well three targeted cancer drugs work on their own or together to treat patients with EGFR+ non-small cell lung cancers that have spread to other parts of the body.
 

This trial is treating patients with non-small cell lung cancer.

This is a systemic therapy trial.

You may be able to join this trial if:

  • Your cancer has spread to other parts of the body.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.
  • You have had certain treatments, surgical procedures or drugs.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

A Phase 3, Randomized Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib Versus Lazertinib as First-Line Treatment in Patients With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer.

Commercial Sponsor

Janssen-Cilag Pty Ltd

Summary

Eligible patients will be randomised into Arm A, Arm B or Arm C of the trial, receiving different combinations of treatment depending on which Arm they are assigned. Patients in Arm A will receive intravenous Amivantamab at a dose adjusted to their body weight, once weekly in Cycle 1 and then every 2 weeks in subsequent cycles. These patients (in Arm A) will also receive an oral dose of Lazertinib (240mg) once daily. Patients in Arm B will receive an oral dose of Osimertinib (80mg), plus a Lazertinib-matching placebo (240mg) once daily. Patients in Arm C will receive oral Lazertinib (240mg), plus an Osimertinib-matching placebo (80mg) once daily.

Recruiting Hospitals Read MoreRead more

Austin Health
Heidelberg
Ms Samantha Chakar
samantha.chakar@austin.org.au
03 9496 3088

Cabrini Education and Research Precinct
Malvern
Li Hoon Lai
lihoonlai@cabrini.com.au
(03) 9508 3421

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.

Next